These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9848508)

  • 1. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent.
    Kennedy AR
    Am J Clin Nutr; 1998 Dec; 68(6 Suppl):1406S-1412S. PubMed ID: 9848508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteases, protease inhibitors and radiation carcinogenesis.
    Kennedy AR
    Int J Radiat Biol; 2023; 99(6):882-890. PubMed ID: 34325613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB; Kennedy AR; Wan XS; Atiba J; McLaren CE; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):43-7. PubMed ID: 10667462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis.
    Kennedy AR; Billings PC; Wan XS; Newberne PM
    Nutr Cancer; 2002; 43(2):174-86. PubMed ID: 12588698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
    Wan XS; Serota DG; Ware JH; Crowell JA; Kennedy AR
    Nutr Cancer; 2002; 43(2):167-73. PubMed ID: 12588697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of carcinogenesis by protease inhibitors.
    Kennedy AR
    Cancer Res; 1994 Apr; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
    Kennedy AR; Szuhaj BF; Newberne PM; Billings PC
    Nutr Cancer; 1993; 19(3):281-302. PubMed ID: 8346077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells.
    Zhang L; Wan XS; Donahue JJ; Ware JH; Kennedy AR
    Nutr Cancer; 1999; 33(2):165-73. PubMed ID: 10368812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemopreventive agents: protease inhibitors.
    Kennedy AR
    Pharmacol Ther; 1998 Jun; 78(3):167-209. PubMed ID: 9690817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.
    Gran B; Tabibzadeh N; Martin A; Ventura ES; Ware JH; Zhang GX; Parr JL; Kennedy AR; Rostami AM
    Mult Scler; 2006 Dec; 12(6):688-97. PubMed ID: 17262995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis.
    Touil T; Ciric B; Ventura E; Shindler KS; Gran B; Rostami A
    J Neurol Sci; 2008 Aug; 271(1-2):191-202. PubMed ID: 18544456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA.
    Kennedy AR; Billings PC; Maki PA; Newberne P
    Nutr Cancer; 1993; 19(2):191-200. PubMed ID: 8502589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer.
    Meyskens FL
    Ann N Y Acad Sci; 2001 Dec; 952():116-23. PubMed ID: 11795430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay.
    Wan XS; Lu LJ; Anderson KE; Ware JH; Kennedy AR
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):741-7. PubMed ID: 10919746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells.
    Kennedy AR; Wan XS
    Prostate; 2002 Feb; 50(2):125-33. PubMed ID: 11816021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
    Armstrong WB; Kennedy AR; Wan XS; Taylor TH; Nguyen QA; Jensen J; Thompson W; Lagerberg W; Meyskens FL
    Clin Cancer Res; 2000 Dec; 6(12):4684-91. PubMed ID: 11156220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity.
    Malkowicz SB; Liu SP; Broderick GA; Wein AJ; Kennedy AR; Levin RM
    Neurourol Urodyn; 2003; 22(1):54-7. PubMed ID: 12478602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum.
    Kennedy CW; Donahue JJ; Wan XS
    Nutr Cancer; 1996; 26(2):209-17. PubMed ID: 8875558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer prevention by protease inhibitors.
    Kennedy AR
    Prev Med; 1993 Sep; 22(5):796-811. PubMed ID: 8234219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with soybean-derived Bowman Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude mice.
    Wan XS; Ware JH; Zhang L; Newberne PM; Evans SM; Clark LC; Kennedy AR
    Prostate; 1999 Dec; 41(4):243-52. PubMed ID: 10544297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.